Patients with hidradenitis suppurativa typically have a history of prolonged clinical courses with numerous treatments undertaken to provide relief. Treatments include topical antibiotics/antimicrobials, oral steroids, oral antibiotics, and surgical procedures. Over the past decade, biologics have emerged as an encouraging treatment option for patients with moderate-to-severe-disease. There are three biologics currently approved for HS: adalimumab (TNF-a inhibitor), secukinumab (IL-17 inhibitor), and, most recently, bimekizumab (IL-17A/F inhibitor). Bimekizumab has been shown to be efficacious and safe in patients with moderate-to-severe HS with a favorable side effect profile. Based on available trial data in psoriasis and psoriatic arthritis patients, bimekizumab may be an ideal treatment option for those who are non-responders to the other approved biologics.